New Jersey hospital performs 4,000th TAVR procedure

The Gagnon Cardiovascular Institute at Morristown Medical Center (MMC) in Morristown, New Jersey, has now performed more than 4,000 transcatheter aortic valve replacement (TAVR) procedures, the hospital announced in Feb. 6. This includes more than 600 TAVR procedures in 2022 alone.  

Back in 2011, MMC was the first hospital in New Jersey to offer TAVR as a treatment option for severe aortic stenosis. Now, more than a decade later, the hospital is home to one of the biggest TAVR programs in the United States. It received the American College of Cardiology's Transcatheter Valve Certification in 2021.

“Our team celebrates this milestone along with our patients as we continue to see evidence of successful outcomes for those who undergo TAVR procedures,” interventional cardiologist Philippe Genereux, MD, medical director of the Gagnon Cardiovascular Institute’s structural heart program, said in a prepared statement. “We are proud that we continue to play such a critical role in leading advancements in interventional cardiology and providing the highest level of cardiac care.”

In related news, Morristown Medical Center announced that Genereux was named one of Clarivate’s Highly Cited Researchers in the company’s 2022 rankings. This is his fourth year being included in the list.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.